

Technology Advisory Committee D Interests Register

Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus - Review of TA397 [ID1591]

Publication Date: 15 December 2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Matthew Bradley	TAC Committee Member	Conflict	Professor Bradley is an employee of the manufacturer of belimumab	26.04.2021	26.04.2021	N/A	As a direct conflict Dr Bradley did not attend the meeting for this topic.
Professor Chris Edwards	Clinical expert	Financial and professional	Professor Edwards has received honoraria for attending advisory boards and speaking events from GSK & Roche. He is an author on publications related to the BILAG biologics registry in the UK and a member of the BILAG group.	21.09.2020	12.05.2021	N/A	It was agreed that this declaration would not prevent Professor Edwards from providing expert advice to the committee.
Dr Peter Lanyon	Patient expert	Professional	Dr Lanyon is the National Clinical Lead for Rheumatology, GIRFT Programme and NHS Improvement and co-chair of Autoimmune Rheumatic Disease Alliance (RAIRDA) – whose	18.09.2020	12.05.2021	N/A	It was agreed that this declaration would not prevent Dr Lanyon from providing expert advice to the committee.

			membership includes LUPUS UK.				
Dr Ivan Koychev	TAC Committee Member	Financial	Ivan has worked on a project developing digital technologies for monitoring cognition funded and done in collaboration with Roche.	16.09.2021	16.09.2021	N/A	It was agreed that his declaration would not prevent Ivan from participating in this section of the meeting.